Double Bond Pharmaceutical International Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Igor Lokot

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	9.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Igor Lokot (52 yo)

9.6yrs

Görev süresi

Mr. Igor Lokot, PhD, serves as the Chief Executive Officer of Double Bond Pharmaceutical International AB (Publ) and serves as its President. Mr. Lokot served as Head of Research at Oasmia Pharmaceutical A...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Igor Lokot	CEO, President & Director	9.6yrs	Veri yok	Veri yok
Sergey Yanitsky	Director	9.6yrs	Veri yok	Veri yok
Sanna Rejnlander	Chairman	2.5yrs	Veri yok	Veri yok
Irina Zaitseva	Director	2.5yrs	Veri yok	Veri yok

6.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DBP B 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

Double Bond Pharmaceutical International Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Double Bond Pharmaceutical International AB (publ), Annual General Meeting, Apr 25, 2024

No independent directors

Recent updates

Double Bond Pharmaceutical International AB (publ) to Report Q3, 2024 Results on Nov 25, 2024

Double Bond Pharmaceutical International AB Announces Transition of the Si053 Clinical Trials Protocol to A New Clinical Trial Information System Has Been Completed

Second quarter 2024 earnings released: kr0.05 loss per share (vs kr0.04 loss in 2Q 2023)

Double Bond Pharmaceutical International AB (publ) to Report Q2, 2024 Results on Aug 26, 2024

Double Bond Pharmaceutical International AB (publ) to Report Q1, 2024 Results on May 24, 2024

Double Bond Pharmaceutical International AB (publ), Annual General Meeting, Apr 25, 2024

Full year 2023 earnings released: kr0.19 loss per share (vs kr0.24 loss in FY 2022)

New major risk - Shareholder dilution

Double Bond Pharmaceutical International AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

DBP International AB Announces Canadian Patent for Temodex / SI-053 Is Granted

Double Bond Pharmaceutical International AB (publ) to Report Q3, 2023 Results on Nov 24, 2023

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Double Bond Pharmaceutical International AB (publ) to Report Q2, 2023 Results on Aug 25, 2023

Double Bond Pharmaceutical International AB (publ) to Report Fiscal Year 2022 Final Results on Feb 24, 2023

Double Bond Pharmaceutical International AB (publ) Announces Receipt of Favorable Response for SI-053 from the Ethics Commission of the Faculty of Medicine of Cologne University in Germany

No independent directors

DBP International AB Receives Australian Patent for Temodex / SI-053

Second quarter 2022 earnings released

First quarter 2022 earnings released

Double Bond Pharmaceutical International AB (Publ) Receives Positive Response for SI-053 from the Federal Institute for Drugs and Medical Devices in Germany

Double Bond Pharmaceutical International AB (Publ) Receives Japanese Patent for Temodex / SI-053

DBP International AB Announces New Patent for SA-033 Is Granted in Japan

Double Bond Pharmaceutical International AB Positive Response for Si-053 from Ethical Committee in the Netherlands Has Been Received

Double Bond Pharmaceutical International AB Announces Clinical Batch of Si-053 Has Been Manufactured for the Upcoming Clinical Trial Phase 1

Double Bond Pharmaceutical International AB Takes Final Step Towards the Start of the Phase 1 Clinical Trial of Its Front-Line Product SI-053

DBP International Announces IMPD for the SI-053 phase I trial is finalized - Nine Out of Ten Milestones for the Clinical Trial of SI-053 Have Been Completed

Double Bond Pharmaceutical International AB (Publ) Takes Step Further Towards the Start of the Phase 1 Clinical Trial of its Front-Line Product SI-053 in Patients with Glioblastoma

Double Bond Pharmaceutical International AB (Publ) Takes Step Further Towards the Start of the Phase 1 Clinical Trial of It's Front-Line Product Si-053

First quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 1Q 2020)

Full year 2020 earnings released: kr0.41 loss per share (vs kr0.30 loss in FY 2019)

New 90-day low: kr2.21

New 90-day low: kr2.40

Double Bond Pharmaceutical International AB (publ) Announces Positive Results from Its SI-053 in Vivo Pharmacokinetic Study in Rats

New 90-day low: kr2.77

Double Bond Pharmaceutical International AB (publ) Announces Si-053 Efficacy Successfully Proven in Vivo Study in Mice

New 90-day low: kr3.21

Double Bond Pharmaceutical International AB (Publ) Receives Information on Granting Us Patent Application Concerning Temodex / Si-053

Double Bond Pharmaceutical Concludes Key Opinion Leader Meeting Resulted in Fine-Tuning the Phase 1 Clinical Plan

First half earnings released

New 90-day high - kr4.08

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş